What is Triastek?
Founded in 2015 by Dr. Senping Cheng and Dr. Xiaoling Li, Triastek is dedicated to revolutionizing the pharmaceutical industry through its novel 3D printing technology platform. By integrating advanced engineering with pharmaceutical science, the company enables precise dosage form design and intelligent manufacturing processes. Triastek operates through a dual-business model, focusing on both in-house product development and strategic co-development partnerships with top-tier multinational and domestic pharmaceutical corporations. This dual-track strategy allows the company to maintain a robust pipeline while leveraging the distribution and regulatory expertise of established industry partners.
How much funding has Triastek raised?
Triastek has raised a total of $85.4M across 3 funding rounds:
Series A
$15M
Series B
$50M
Other Financing Round
$20.4M
Series A (2020): $15M with participation from Dalton Venrures, Zheng Xiaodong, Shangahi Tofflon Science, and Yunqi Partners
Series B (2021): $50M led by Dalton Venture, Matrix Partners China, Morningside Ventures, CPE, and Shanghai Sci-Tech Innovation Center Capital
Other Financing Round (2023): $20.4M supported by Jiangsu Guoxin Investment Group
Key Investors in Triastek
Dalton Venture
Dalton Venture focuses on early-stage investments and industrial mergers and acquisitions in the health sector, particularly emphasizing medical services and innovative medical technologies.
Jiangsu Guoxin Investment Group
Jiangsu Guoxin Investment Group is a large-scale state-owned entity authorized by the provincial government to manage state-owned assets and invest in strategic industries including energy, finance, and technology.
Matrix Partners China
Matrix Partners China is a prominent venture capital firm that provides comprehensive support to high-growth companies, focusing on technology-driven innovation and market disruption.
What's next for Triastek?
With the recent infusion of capital, Triastek is well-positioned to scale its intelligent manufacturing capabilities and expand its footprint in the global pharmaceutical market. The company's strategic roadmap emphasizes the acceleration of its co-development projects and the further refinement of its 3D printing technology to meet the evolving needs of personalized medicine. As the industry shifts toward more efficient and flexible manufacturing solutions, Triastek's focus on technological innovation and strategic partnerships will likely serve as a catalyst for its continued growth and market leadership in the pharmaceutical sector.
See full Triastek company page
